eMedicine Specialties > Oncology > Carcinomas of the Gastrointestinal Tract

Fibrolamellar Carcinoma: Differential Diagnoses & Workup

Author: Michael A Choti, MD, MBA, Jacob C Handelsman Professor of Surgery, Professor of Oncology and Engineering, Johns Hopkins University School of Medicine
Coauthor(s): Hari Nathan, MD, House Staff, Department of Surgery, The Johns Hopkins Hospital; Postdoctoral Fellow, Department of Surgery, The Johns Hopkins University School of Medicine
Contributor Information and Disclosures

Updated: Mar 9, 2009

Differential Diagnoses

Hemangiomas, Hepatic
Hepatic Carcinoma, Primary
Hepatocellular Adenoma

Other Problems to Be Considered

All hepatic tumors that may demonstrate a scar are as follows:30

Focal nodular hyperplasia (FNH)
Hepatocellular adenoma
Hepatocellular carcinoma (HCC)
Intrahepatic cholangiocarcinoma (ICC)
Giant hemangioma 
Hepatic metastasis

Case reports of synchronous or metachronous liver tumors in patients with fibrolamellar carcinoma (FLC) are as follows:

Focal nodular hyperplasia10,11,12,13
Hepatic adenoma

Typical hepatocellular carcinoma, synchronous31,32,33,34,35 or metachronous (initially thought to be fibrolamellar carcinoma recurrence)36,37
Intrahepatic cholangiocarcinoma38

Workup

Laboratory Studies

  • Hepatic enzymes
    • Mild elevations of serum aspartate and alanine aminotransferases (AST and ALT)2 and alkaline phosphatase may be identified but are commonly absent.22
    • Elevation of serum bilirubin is rarely identified, but subclinical biliary obstruction may be relatively common, as 40% of cases demonstrate intrahepatic biliary ductal dilatation on imaging studies.39
  • α-Fetoprotein (AFP) levels are typically normal but may be elevated. Less than 10% of patients with fibrolamellar carcinoma (FLC) have AFP levels greater than 200 ng/mL,35 and even this finding may in part represent misclassification of hepatocellular carcinoma (HCC) as fibrolamellar carcinoma.7,20
  • Other circulating tumor markers
    • Serum carcinoembryonic antigen (CEA) can be elevated on occasion.
    • An association between fibrolamellar carcinoma and increased serum binding capacity of vitamin B-12 has been reported.40,41,24 Likewise, elevated serum neurotensin levels have been reported in association with fibrolamellar carcinoma.42 Neither test can accurately differentiate fibrolamellar carcinoma from other liver tumors, and neither test is useful as a screening modality. However, these levels may have utility for following a tumor's response to chemotherapy or for monitoring disease recurrence in patients following tumor resection.

Imaging Studies

  • Radiography
    • This tumor typically presents as a solitary mass in an otherwise normal appearing liver. Fibrolamellar carcinoma can be quite large, and a visible central scar is noted in 20-60% of cases.43
    • The radiologic differential diagnosis of fibrolamellar carcinoma includes the following benign and malignant hepatic tumors:
      • Focal nodular hyperplasia (FNH)
      • Hepatocellular adenoma
      • Hepatocellular carcinoma (HCC)
      • Intrahepatic cholangiocarcinoma
      • Giant hepatic hemangioma
      • Hypervascular metastases
    • Fibrolamellar carcinoma must be carefully differentiated from focal nodular hyperplasia because their management differs. Epidemiologic characteristics are similar in that both lesions occur in young healthy patients who usually do not have a history of cirrhosis or liver disease. However, fibrolamellar carcinoma requires aggressive treatment by liver resection, while focal nodular hyperplasia, a benign disease, does not require treatment unless the patient is symptomatic.
    • The imaging study of choice for staging is computed tomography (CT) scan.
  • Computed tomography (CT) scan
    • Fibrolamellar carcinoma usually appears as a hypoattenuated, well-defined, solitary mass on a nonenhanced CT scan. When a dynamically enhanced CT scan is used with arterial- and portal venous-phase contrast, the cellular portion enhances prominently and is heterogeneous, consistent with its vascular characteristics.
    • The central scar (Image 2), if present, can be viewed on nonenhanced and arterial phase scans; however, it is best viewed on delayed images because the unscarred portion of the mass becomes more homogeneous. Note that the fibrous scar in fibrolamellar carcinoma, when present, typically does not enhance.44 This is in contrast to focal nodular hyperplasia, in which the central scar, which is in reality a vascular entity, enhances on arterial-phase CT scan images.45 This difference generally distinguishes fibrolamellar carcinoma from focal nodular hyperplasia but is not absolute, as up to 25% of fibrolamellar carcinoma cases may in fact demonstrate delayed enhancement of the central scar.

    • CT scan showing fibrolamellar carcinoma with a la...

      CT scan showing fibrolamellar carcinoma with a large stellate central scar.

      [ CLOSE WINDOW ]
      CT scan showing fibrolamellar carcinoma with a la...

      CT scan showing fibrolamellar carcinoma with a large stellate central scar.

    • Calcifications are present in 33-55% of fibrolamellar carcinoma and are usually located within the central scar but may less commonly be located at the tumor periphery.43,46
    • Pseudoencapsulation of the tumor, caused by compression of adjacent liver parenchyma, is present in up to 15% of cases. However, true encapsulation is more characteristics of typical hepatocellular carcinoma.
    • Retraction of the adjacent Glisson capsule can occur in up to 10% of fibrolamellar carcinoma cases, but it is also found with other primary liver malignancies. However, Glisson capsule retraction argues against a benign lesion such as focal nodular hyperplasia.47
    • As noted above, the ability to differentiate fibrolamellar carcinoma from other lesions that also demonstrate central scars is useful. In a blinded retrospective review of CT scans of 64 patients with liver tumors (20 fibrolamellar carcinoma, 29 focal nodular hyperplasia, and 15 hemangiomas), findings that were useful in differentiating fibrolamellar carcinoma from focal nodular hyperplasia and large hemangiomas were as follows:48
      • Tumor size greater than 10 cm (focal nodular hyperplasia usually <5 cm)
      • Nodular centripetal enhancement (typical of hemangioma)
      • Invasion of hepatic vessels or bile ducts (rules out focal nodular hyperplasia and hemangioma)
      • Scar width greater than 2 cm (suggests fibrolamellar carcinoma or hemangioma over focal nodular hyperplasia)
      • Heterogeneity (typical of fibrolamellar carcinoma, also found in hemangioma but in a characteristic pattern of nodular centripetal enhancement, uncommon in focal nodular hyperplasia)
      • Isoattenuation with blood vessels (suggests focal nodular hyperplasia over fibrolamellar carcinoma or hemangioma)
      • Extrahepatic metastases (rules out focal nodular hyperplasia and hemangioma)
      • Calcification (suggests fibrolamellar carcinoma over focal nodular hyperplasia or hemangioma)
      • Surface lobulation (suggests fibrolamellar carcinoma or hemangioma over focal nodular hyperplasia)
      • Almost isoattenuating on portal venous phase images (favors fibrolamellar carcinoma or focal nodular hyperplasia over hemangioma)
  • Magnetic resonance imaging (MRI)
    • MRI commonly shows a large, lobulated, homogeneous mass (Image 3) that is hypointense relative to normal liver parenchyma on T1-weighted images. T2-weighted images (Image 4) show a hyperintense mass relative to the liver and a heterogeneous pattern in most patients.

    • T1-weighted MRI of a fibrolamellar carcinoma in t...

      T1-weighted MRI of a fibrolamellar carcinoma in the left lobe of the liver.

      [ CLOSE WINDOW ]
      T1-weighted MRI of a fibrolamellar carcinoma in t...

      T1-weighted MRI of a fibrolamellar carcinoma in the left lobe of the liver.


    • T2-weighted MRI of a fibrolamellar carcinoma in t...

      T2-weighted MRI of a fibrolamellar carcinoma in the left lobe of the liver, demonstrating a heterogeneous appearance with a central scar.

      [ CLOSE WINDOW ]
      T2-weighted MRI of a fibrolamellar carcinoma in t...

      T2-weighted MRI of a fibrolamellar carcinoma in the left lobe of the liver, demonstrating a heterogeneous appearance with a central scar.

    • If a fibrous scar is present, it is usually hypointense on all MRI images.44,49 The fact that fibronodular hyperplasia demonstrates a hyperintense scar on MRI can be used to differentiate these tumors, although fibrolamellar carcinoma scars can uncommonly demonstrate hyperintensity on T2-weighted images.50,51
    • The enhancement pattern seen for fibrolamellar carcinoma on gadolinium-enhanced MRI parallels that seen on CT scan.
  • Ultrasonography, which is often the initial study performed for right upper quadrant abdominal pain, commonly shows fibrolamellar carcinoma as a solitary, well-defined mass with variable echotexture. Tumors with mixed echotexture are most common (60%) and are predominantly hyperechoic or isoechoic. The sensitivity of ultrasonography for detecting a central scar is only 33-60% (as compared with CT and pathological analysis),43,46 and when present is visualized as a central area of hyperechogenicity. Ultrasonography is less accurate than CT scan or MRI for evaluation of lymph node involvement and staging.52,53,54,55
  • Other imaging studies
    • Plain abdominal radiographs have only a limited role in diagnosing or distinguishing liver lesions. However, fibrolamellar carcinoma can be associated with calcifications in a nodular or stellate pattern in up to 40% of abdominal radiographs of patients with fibrolamellar carcinoma.
    • Angiography may demonstrate a hypervascular lesion with a dense tumor blush and an avascular region corresponding to the central scar. However, it is of limited value in diagnosing fibrolamellar carcinoma. On the other hand, it does have utility for defining portal venous and hepatic arterial anatomy and may aid in preoperative planning by allowing assessment of vascular invasion.
    • Positron emission tomography (PET) scanning is generally of limited value in typical hepatocellular carcinoma because of its low sensitivity, but more aggressive or dedifferentiated hepatocellular carcinoma tumors demonstrate enhanced tracer uptake.56 Because fibrolamellar carcinomas are generally well-differentiated tumors, PET scanning is unlikely to be of great utility. One case report has demonstrated the successful use of PET scanning to stage fibrolamellar carcinoma, but this case involved a relatively large and aggressive tumor.57

Procedures

  • Fine-needle aspiration biopsy
    • In some patients, fine needle aspiration biopsy (FNAB) can allow a histopathologic diagnosis to be made prior to operative intervention.
    • FNAB should not be performed if the tumor is deemed resectable based upon imaging studies. But, if the tumor is unresectable, FNAB may facilitate a tissue diagnosis in order for the oncologist to select the appropriate chemotherapy regimen.
    • FNAB should be used in cases when the diagnosis is unclear, such as when focal nodular hyperplasia is considered in an asymptomatic patient. This is important because distinguishing fibrolamellar carcinoma from focal nodular hyperplasia has implications for treatment and prognosis.
    • The cytologic findings of fibrolamellar carcinoma are very characteristic:58,59,60,61,62
      • Large polygonal tumor cells: A single cell aspirated from a fibrolamellar carcinoma is 3 times the size of a normal hepatocyte and 1.6 times the size of a single cell aspirated from a well-differentiated typical hepatocellular carcinoma.
      • Large nuclei and prominent nucleoli
      • Abundant eosinophilic, granular cytoplasm, such that the N/C ratio is not as high as that for typical hepatocellular carcinoma (despite the large nucleus)
      • Parallel bands of fibrous tissue may be seen in tumor fragments.
  • Core needle biopsy
    • The indications for core needle biopsy and the cytologic appearance of the tumor are as for FNAB.
    • Core needle biopsy is more likely than FNAB to preserve the fibrous lamellae that are important to distinguish fibrolamellar carcinoma from typical hepatocellular carcinoma. As such, core needle biopsy is preferred over FNAB when a percutaneous biopsy is needed.

Histologic Findings

Fibrolamellar carcinoma has a distinct macroscopic and microscopic appearance. Macroscopically, it typically appears as a yellow to pale tan mass ranging in texture from soft to hard and arising in a background of normal, noncirrhotic liver parenchyma.7 The tumors are often large, growing up to 10-20 cm in size,54,63,23,35 and usually solitary (80-90%),23,35,54 although small satellite lesions are occasionally observed. Pseudoencapsulation occasionally occurs, but a true capsule is more suggestive of typical hepatocellular carcinoma. A visible central scar, representing fibrosis rather than a vascular entity as in focal nodular hyperplasia, is noted in 20-60% of cases.43,64,65 Hemorrhage and necrosis are occasionally observed.64

Microscopically, fibrolamellar carcinoma appears as tumor cells growing in sheets or small trabeculae that are separated by fibrous collagen. This results in a characteristic lamellar pattern (Image 5, Image 6).61 These lamellar bands of fibrosis may coalesce, forming the fibrous central scars seen on gross examination.7

Hematoxylin and eosin photomicrograph of fibrolam...

Hematoxylin and eosin photomicrograph of fibrolamellar carcinoma. Note the thick fibrous lamellae within the tumor stroma.

[ CLOSE WINDOW ]
Hematoxylin and eosin photomicrograph of fibrolam...

Hematoxylin and eosin photomicrograph of fibrolamellar carcinoma. Note the thick fibrous lamellae within the tumor stroma.


Masson trichrome stain photomicrograph of fibrola...

Masson trichrome stain photomicrograph of fibrolamellar carcinoma depicting the collagen-containing lamellae within the tumor stroma.

[ CLOSE WINDOW ]
Masson trichrome stain photomicrograph of fibrola...

Masson trichrome stain photomicrograph of fibrolamellar carcinoma depicting the collagen-containing lamellae within the tumor stroma.


The defining cytologic features of fibrolamellar carcinoma are as follows:1,2,3,7,61

  • Large polygonal cells with abundant eosinophilic cytoplasm
  • Large vesiculated nuclei
  • Large nucleoli
Tumor cells may also demonstrate "pale bodies," which are round amphophilic cytoplasmic inclusions, and hyaline bodies.2 Both features are found in roughly 50% of fibrolamellar carcinomas but are not specific for fibrolamellar carcinoma, as they may also be found in typical hepatocellular carcinoma.2 Mitotic figures are less common than in typical hepatocellular carcinoma.7 Copper deposition is often seen in fibrolamellar carcinoma, as in typical hepatocellular carcinoma.7

Immunohistochemical staining can differentiate fibrolamellar carcinoma from non-hepatocellular carcinoma liver tumors but not from typical hepatocellular carcinoma. Fibrolamellar carcinoma demonstrates positive staining for α1-antitrypsin and fibrinogen in most cases and at higher levels than typical hepatocellular carcinoma, while AFP immunoreactivity is usually absent (except in the uncommon circumstance of elevated serum AFP).66 Consistent with their high degree of differentiation, fibrolamellar carcinoma cells express hepatocellular differentiation markers (HepPar) and biliary differentiation markers (cytokeratin 7),6 as well as CD99.67

Staging

CT scan is the imaging study of choice for the staging of fibrolamellar carcinoma. The American Joint Commission on Cancer (AJCC) TNM staging system for fibrolamellar carcinoma is the same as for typical hepatocellular carcinoma. Metastatic spread to regional lymph nodes may be more common in fibrolamellar carcinoma than in typical hepatocellular carcinoma.

More on Fibrolamellar Carcinoma

Overview: Fibrolamellar Carcinoma
Differential Diagnoses & Workup: Fibrolamellar Carcinoma
Treatment & Medication: Fibrolamellar Carcinoma
Follow-up: Fibrolamellar Carcinoma
Multimedia: Fibrolamellar Carcinoma
References
[ CLOSE WINDOW ]

References

  1. Edmondson HA. Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. AMA J Dis Child. Feb 1956;91(2):168-86. [Medline].

  2. Craig JR, Peters RL, Edmondson HA, et al. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer. Jul 15 1980;46(2):372-9. [Medline].

  3. Berman MM, Libbey NP, Foster JH. Hepatocellular carcinoma. Polygonal cell type with fibrous stroma--an atypical variant with a favorable prognosis. Cancer. Sep 15 1980;46(6):1448-55. [Medline].

  4. Farhi DC, Shikes RH, Murari PJ, et al. Hepatocellular carcinoma in young people. Cancer. Oct 15 1983;52(8):1516-25. [Medline].

  5. Stromeyer FW, Ishak KG, Gerber MA, et al. Ground-glass cells in hepatocellular carcinoma. Am J Clin Pathol. Sep 1980;74(3):254-8. [Medline].

  6. Klein WM, Molmenti EP, Colombani PM, et al. Primary liver carcinoma arising in people younger than 30 years. Am J Clin Pathol. Oct 2005;124(4):512-8. [Medline].

  7. Torbenson M. Review of the clinicopathologic features of fibrolamellar carcinoma. Adv Anat Pathol. May 2007;14(3):217-23. [Medline].

  8. Kannangai R, Vivekanandan P, Martinez-Murillo F, et al. Fibrolamellar carcinomas show overexpression of genes in the RAS, MAPK, PIK3, and xenobiotic degradation pathways. Hum Pathol. Apr 2007;38(4):639-44. [Medline].

  9. Vivekanandan P, Torbenson M. Epigenetic instability is rare in fibrolamellar carcinomas but common in viral-associated hepatocellular carcinomas. Mod Pathol. Jun 2008;21(6):670-5. [Medline].

  10. Farhi DC, Shikes RH, Silverberg SG. Ultrastructure of fibrolamellar oncocytic hepatoma. Cancer. Aug 15 1982;50(4):702-9. [Medline].

  11. Saul SH, Titelbaum DS, Gansler TS, et al. The fibrolamellar variant of hepatocellular carcinoma. Its association with focal nodular hyperplasia. Cancer. Dec 15 1987;60(12):3049-55. [Medline].

  12. Imkie M, Myers SA, Li Y, et al. Fibrolamellar hepatocellular carcinoma arising in a background of focal nodular hyperplasia: a report of 2 cases. J Reprod Med. Aug 2005;50(8):633-7. [Medline].

  13. Vecchio FM, Fabiano A, Ghirlanda G, et al. Fibrolamellar carcinoma of the liver: the malignant counterpart of focal nodular hyperplasia with oncocytic change. Am J Clin Pathol. Apr 1984;81(4):521-6. [Medline].

  14. Vecchio FM. Fibrolamellar carcinoma of the liver: a distinct entity within the hepatocellular tumors. A review. Appl Pathol. 1988;6(2):139-48. [Medline].

  15. El-Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology. Mar 2004;39(3):798-803. [Medline].

  16. Arista-Nasr J, Gutierrez-Villalobos L, Nuncio J, et al. Fibrolamellar hepatocellular carcinoma in mexican patients. Pathol Oncol Res. 2002;8(2):133-7. [Medline].

  17. Haas JE, Muczynski KA, Krailo M, et al. Histopathology and prognosis in childhood hepatoblastoma and hepatocarcinoma. Cancer. Sep 1 1989;64(5):1082-95. [Medline].

  18. Katzenstein HM, Krailo MD, Malogolowkin MH, et al. Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer. Apr 15 2003;97(8):2006-12. [Medline].

  19. Nagorney DM, Adson MA, Weiland LH, et al. Fibrolamellar hepatoma. Am J Surg. Jan 1985;149(1):113-9. [Medline].

  20. Kakar S, Burgart LJ, Batts KP, et al. Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis. Mod Pathol. Nov 2005;18(11):1417-23. [Medline].

  21. Saab S, Yao F. Fibrolamellar hepatocellular carcinoma. Case reports and a review of the literature. Dig Dis Sci. Oct 1996;41(10):1981-5. [Medline].

  22. Hemming AW, Langer B, Sheiner P, et al. Aggressive surgical management of fibrolamellar hepatocellular carcinoma. J Gastrointest Surg. Jul-Aug 1997;1(4):342-6. [Medline].

  23. El-Gazzaz G, Wong W, El-Hadary MK, et al. Outcome of liver resection and transplantation for fibrolamellar hepatocellular carcinoma. Transpl Int. 2000;13 Suppl 1:S406-9. [Medline].

  24. Kanai T, Takabayashi T, Kawano Y, et al. A case of postoperative recurrence of fibrolamellar hepatocellular carcinoma with increased vitamin B12 binding capacity in a young Japanese female. Jpn J Clin Oncol. Jun 2004;34(6):346-51. [Medline].

  25. Debray D, Pariente D, Fabre M, et al. Fibrolamellar hepatocellular carcinoma: report of a case mimicking a liver abscess. J Pediatr Gastroenterol Nutr. Nov 1994;19(4):468-72. [Medline].

  26. Soyer P, Roche A, Levesque M. Fibrolamellar hepatocellular carcinoma presenting with obstructive jaundice. A report of two cases. Eur J Radiol. Nov-Dec 1991;13(3):196-8. [Medline].

  27. Eckstein RP, Bambach CP, Stiel D, et al. Fibrolamellar carcinoma as a cause of bile duct obstruction. Pathology. Oct 1988;20(4):326-31. [Medline].

  28. Agarwal VR, Takayama K, Van Wyk JJ, et al. Molecular basis of severe gynecomastia associated with aromatase expression in a fibrolamellar hepatocellular carcinoma. J Clin Endocrinol Metab. May 1998;83(5):1797-800. [Medline].

  29. McCloskey JJ, Germain-Lee EL, Perman JA, et al. Gynecomastia as a presenting sign of fibrolamellar carcinoma of the liver. Pediatrics. Sep 1988;82(3):379-82. [Medline].

  30. Buetow PC, Pantongrag-Brown L, Buck JL, et al. Focal nodular hyperplasia of the liver: radiologic-pathologic correlation. Radiographics. Mar 1996;16(2):369-88. [Medline].

  31. Okada K, Kim YI, Nakashima K, et al. Fibrolamellar hepatocellular carcinoma coexistent with a hepatocellular carcinoma of common type: report of a case. Surg Today. 1993;23(7):626-31. [Medline].

  32. Okano A, Hajiro K, Takakuwa H, et al. Fibrolamellar carcinoma of the liver with a mixture of ordinary hepatocellular carcinoma: a case report. Am J Gastroenterol. Jul 1998;93(7):1144-5. [Medline].

  33. Seitz G, Zimmermann A, Friess H, Büchler MW. Adult-type hepatocellular carcinoma in the center of a fibrolamellar hepatocellular carcinoma. Hum Pathol. Jul 2002;33(7):765-9. [Medline].

  34. Morise Z, Sugioka A, Mizoguchi Y, et al. Fibrolamellar carcinoma of the liver in a Japanese hepatitis B virus carrier. J Gastroenterol Hepatol. Jul 2005;20(7):1136-8. [Medline].

  35. Stipa F, Yoon SS, Liau KH, et al. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer. Mar 15 2006;106(6):1331-8. [Medline].

  36. Yamamoto H, Watanabe K, Nagata M, et al. Transformation of fibrolamellar carcinoma to common hepatocellular carcinoma in the recurrent lesions of the rectum and the residual liver: a case report. Jpn J Clin Oncol. Sep 1999;29(9):445-7. [Medline].

  37. Chang YC, Dai YC, Chow NH. Fibrolamellar hepatocellular carcinoma with a recurrence of classic hepatocellular carcinoma: a case report and review of Oriental cases. Hepatogastroenterology. Sep-Oct 2003;50(53):1637-40. [Medline].

  38. Tanaka K, Honna T, Kitano Y, et al. Combined fibrolamellar carcinoma and cholangiocarcinoma exhibiting biphenotypic antigen expression: a case report. J Clin Pathol. Aug 2005;58(8):884-7. [Medline].

  39. Ichikawa T, Federle MP, Grazioli L, et al. Fibrolamellar hepatocellular carcinoma: pre- and posttherapy evaluation with CT and MR imaging. Radiology. Oct 2000;217(1):145-51. [Medline].

  40. Paradinas FJ, Melia WM, Wilkinson ML, et al. High serum vitamin B12 binding capacity as a marker of the fibrolamellar variant of hepatocellular carcinoma. Br Med J (Clin Res Ed). Sep 25 1982;285(6345):840-2. [Medline].

  41. Sheppard KJ, Bradbury DA, Davies JM, et al. High serum vitamin B12 binding capacity as a marker of the fibrolamellar variant of hepatocellular carcinoma. Br Med J (Clin Res Ed). Jan 1 1983;286(6358):57. [Medline].

  42. Collier NA, Weinbren K, Bloom SR, et al. Neurotensin secretion by fibrolamellar carcinoma of the liver. Lancet. Mar 10 1984;1(8376):538-40. [Medline].

  43. Brandt DJ, Johnson CD, Stephens DH, et al. Imaging of fibrolamellar hepatocellular carcinoma. AJR Am J Roentgenol. Aug 1988;151(2):295-9. [Medline].

  44. Corrigan K, Semelka RC. Dynamic contrast-enhanced MR imaging of fibrolamellar hepatocellular carcinoma. Abdom Imaging. Mar-Apr 1995;20(2):122-5. [Medline].

  45. Gabata T, Matsui O, Kadoya M, et al. Delayed MR imaging of the liver: correlation of delayed enhancement of hepatic tumors and pathologic appearance. Abdom Imaging. May-Jun 1998;23(3):309-13. [Medline].

  46. Soyer P, Roche A, Levesque M, et al. CT of fibrolamellar hepatocellular carcinoma. J Comput Assist Tomogr. Jul-Aug 1991;15(4):533-8. [Medline].

  47. Soyer P, Bluemke DA, Vissuzaine C, et al. CT of hepatic tumors: prevalence and specificity of retraction of the adjacent liver capsule. AJR Am J Roentgenol. May 1994;162(5):1119-22. [Medline].

  48. Blachar A, Federle MP, Ferris JV, et al. Radiologists' performance in the diagnosis of liver tumors with central scars by using specific CT criteria. Radiology. May 2002;223(2):532-9. [Medline].

  49. Titelbaum DS, Hatabu H, Schiebler ML, et al. Fibrolamellar hepatocellular carcinoma: MR appearance. J Comput Assist Tomogr. Jul-Aug 1988;12(4):588-91. [Medline].

  50. Hamrick-Turner JE, Shipkey FH, Cranston PE. Fibrolamellar hepatocellular carcinoma: MR appearance mimicking focal nodular hyperplasia. J Comput Assist Tomogr. Mar-Apr 1994;18(2):301-4. [Medline].

  51. Hui MS, Choi WM, Perng HL, et al. Fibrolamellar hepatocellular carcinoma--an atypical MR manifestation. Hepatogastroenterology. Mar-Apr 1998;45(20):514-7. [Medline].

  52. Adam A, Gibson RN, Soreide O, et al. The radiology of fibrolamellar hepatoma. Clin Radiol. Jul 1986;37(4):355-8. [Medline].

  53. Miller WJ, Federle MP, Campbell WL. Diagnosis and staging of hepatocellular carcinoma: comparison of CT and sonography in 36 liver transplantation patients. AJR Am J Roentgenol. Aug 1991;157(2):303-6. [Medline].

  54. Stevens WR, Johnson CD, Stephens DH, et al. Fibrolamellar hepatocellular carcinoma: stage at presentation and results of aggressive surgical management. AJR Am J Roentgenol. May 1995;164(5):1153-8. [Medline].

  55. Stevens WR, Johnson CD, Stephens DH, et al. CT findings in hepatocellular carcinoma: correlation of tumor characteristics with causative factors, tumor size, and histologic tumor grade. Radiology. May 1994;191(2):531-7. [Medline].

  56. Trojan J, Schroeder O, Raedle J, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol. Nov 1999;94(11):3314-9. [Medline].

  57. von Falck C, Rodt T, Shin HO, et al. F-18 FDG PET imaging of fibrolamellar hepatocellular carcinoma. Clin Nucl Med. Sep 2008;33(9):633-4. [Medline].

  58. Suen KC, Magee JF, Halparin LS, et al. Fine needle aspiration cytology of fibrolamellar hepatocellular carcinoma. Acta Cytol. Sep-Oct 1985;29(5):867-72. [Medline].

  59. Davenport RD. Cytologic diagnosis of fibrolamellar carcinoma of the liver by fine-needle aspiration. Diagn Cytopathol. 1990;6(4):275-9. [Medline].

  60. Perez-Guillermo M, Masgrau NA, García-Solano J, et al. Cytologic aspect of fibrolamellar hepatocellular carcinoma in fine-needle aspirates. Diagn Cytopathol. Sep 1999;21(3):180-7. [Medline].

  61. Kojiro M. Histopathology of liver cancers. Best Pract Res Clin Gastroenterol. Feb 2005;19(1):39-62. [Medline].

  62. Mansouri D, Van Nhieu JT, Couanet D, et al. Fibrolamellar hepatocellular carcinoma: a case report with cytological features in a sixteen-year-old girl. Diagn Cytopathol. Aug 2006;34(8):568-71. [Medline].

  63. Pinna AD, Iwatsuki S, Lee RG, et al. Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation. Hepatology. Oct 1997;26(4):877-83. [Medline].

  64. Ichikawa T, Federle MP, Grazioli L, et al. Fibrolamellar hepatocellular carcinoma: imaging and pathologic findings in 31 recent cases. Radiology. Nov 1999;213(2):352-61. [Medline].

  65. Pan Y, Wang ZM, Mou LJ, et al. Focal nodular hyperplasia of the liver: pathological analysis of 11 cases. Hepatobiliary Pancreat Dis Int. May 2004;3(2):199-203. [Medline].

  66. Berman MA, Burnham JA, Sheahan DG. Fibrolamellar carcinoma of the liver: an immunohistochemical study of nineteen cases and a review of the literature. Hum Pathol. Jul 1988;19(7):784-94. [Medline].

  67. Vasdev N, Nayak NC. CD99 expression in hepatocellular carcinoma: an immunohistochemical study in the fibrolamellar and common variant of the tumour. Indian J Pathol Microbiol. Oct 2003;46(4):625-9. [Medline].

  68. Sitzmann JV. Conversion of unresectable to resectable liver cancer: an approach and follow-up study. World J Surg. Nov-Dec 1995;19(6):790-4. [Medline].

  69. Soyer P, Roche A, Rougier P, et al. [Nonresectable fibrolamellar hepatocellular carcinoma: outcome of 4 cases treated by intra-arterial chemotherapy]. J Belge Radiol. Dec 1992;75(6):463-8. [Medline].

  70. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. Jul 24 2008;359(4):378-90. [Medline].

  71. Patt YZ, Hassan MM, Lozano RD, et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol. Feb 1 2003;21(3):421-7. [Medline].

  72. Pichlmayr R, Weimann A, Tusch G, et al. Indications and Role of Liver Transplantation for Malignant Tumors. Oncologist. 1997;2(3):164-170. [Medline].

  73. Schlitt HJ, Neipp M, Weimann A, et al. Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol. Jan 1999;17(1):324-31. [Medline].

  74. Bartlett D, Di Bisceglie A, Dawson L. Cancer of the Liver. In: De Vita VT, Lawrence TS, Rosenberg S. Cancer: Principles & Practice of Oncology. 1. 8th ed. Philadelphia, Pa: Lippincott, Williams and Wilkins; 2008:1129-56.

  75. Epstein BE, Pajak TF, Haulk TL, et al. Metastatic nonresectable fibrolamellar hepatoma: prognostic features and natural history. Am J Clin Oncol. Feb 1999;22(1):22-8. [Medline].

  76. Friedman AC, Lichtenstein JE, Goodman Z, et al. Fibrolamellar hepatocellular carcinoma. Radiology. Dec 1985;157(3):583-7. [Medline].

  77. Lamberts R, Nitsche R, de Vivie RE, et al. Budd-Chiari syndrome as the primary manifestation of a fibrolamellar hepatocellular carcinoma. Digestion. 1992;53(3-4):200-9. [Medline].

  78. McLarney JK, Rucker PT, Bender GN, et al. Fibrolamellar carcinoma of the liver: radiologic-pathologic correlation. Radiographics. Mar-Apr 1999;19(2):453-71. [Medline].

  79. Steinmüller T, Jonas S, Neuhaus P. Review article: liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther. Jun 2003;17 Suppl 2:138-44. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

fibrolamellar carcinoma review article, fibrolamellar cancer review article, fibrolamellar cancer treatment, fibrolamellar cancer diagnosis, fibrolamellar cancer pictures, fibrolamellar cancer image, fibrolamellar carcinoma treatment, fibrolamellar carcinoma diagnosis, fibrolamellar carcinoma pictures, fibrolamellar carcinoma images, liver tumor, liver cancer, hepatic cancer, fibrolamellar hepatoma, hepatocellular carcinoma with lamellar fibrosis, FLC, hepatocellular cancer, HCC, eosinophilic hepatocellular carcinoma with lamellar fibrosis, polygonal cell with fibrous stroma, eosinophilic glassy cell hepatoma, fibrolamellar oncocytic hepatoma, fibrolamellar carcinoma

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Michael A Choti, MD, MBA, Jacob C Handelsman Professor of Surgery, Professor of Oncology and Engineering, Johns Hopkins University School of Medicine
Michael A Choti, MD, MBA is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Surgeons, American Hepato-Pancreato-Biliary Association, American Society of Clinical Oncology, American Surgical Association, Association for Academic Surgery, International Hepato-Pancreato-Biliary Association, Society for Surgery of the Alimentary Tract, Society of Surgical Oncology, and Society of University Surgeons
Disclosure: Nothing to disclose.

Coauthor(s)

Hari Nathan, MD, House Staff, Department of Surgery, The Johns Hopkins Hospital; Postdoctoral Fellow, Department of Surgery, The Johns Hopkins University School of Medicine
Hari Nathan, MD is a member of the following medical societies: American College of Surgeons, American Hepato-Pancreato-Biliary Association, Association for Academic Surgery, and Society for Surgery of the Alimentary Tract
Disclosure: Nothing to disclose.

Medical Editor

Lodovico Balducci, MD, Professor of Oncology and Medicine, University of South Florida College of Medicine; Division Chief, Senior Adult Oncology Program, H Lee Moffitt Cancer Center and Research Institute
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Troy H Guthrie, Jr, MD, Director of Cancer Institute, Baptist Medical Center
Troy H Guthrie, Jr, MD is a member of the following medical societies: American Federation for Medical Research, American Medical Association, American Society of Hematology, Florida Medical Association, Medical Association of Georgia, and Southern Medical Association
Disclosure: Nothing to disclose.

CME Editor

Rajalaxmi McKenna, MD, FACP, Southwest Medical Consultants, SC, Department of Medicine, Good Samaritan Hospital, Advocate Health Systems
Rajalaxmi McKenna, MD, FACP is a member of the following medical societies: American Society of Clinical Oncology, American Society of Hematology, and International Society on Thrombosis and Haemostasis
Disclosure: Nothing to disclose.

Chief Editor

Jules E Harris, MD, Clinical Professor of Medicine, Division of Hematology/Medical Oncology, Department of Internal Medicine, University of Arizona College of Medicine at Tucson; Consulting Staff, Arizona Cancer Center
Jules E Harris, MD is a member of the following medical societies: American Association for Cancer Research, American Association for the Advancement of Science, American Association of Immunologists, American Society of Hematology, and Central Society for Clinical Research
Disclosure: GlobeImmune Salary Consulting; Amplimed Consulting fee Consulting; FibroGen Consulting fee Consulting

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.